Erasca Inc. Faces Allegations of Trade Secret Misappropriation from Revolution Medicines Concerning ERAS-0015 - SEC Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Source: moomoo
- Allegations of Misappropriation: The article discusses allegations related to the misappropriation of trade secrets in the context of a case involving ERASCA Inc.
- Legal Proceedings: It highlights the ongoing legal proceedings and the implications of the allegations for the company and its operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.320
Low
2.00
Averages
5.50
High
11.00
Current: 18.320
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Securities Fraud Class Action Lawsuit
- Class Action Reminder: Bernstein Liebhard LLP reminds investors of Erasca, Inc. (NASDAQ: ERAS) about the August 10, 2026 deadline for a securities fraud class action lawsuit, urging investors to submit forms promptly to participate in the litigation.
- Lawsuit Background: The lawsuit represents investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, alleging violations of the Securities Exchange Act of 1934 by the company and certain senior officers for making materially false and misleading statements regarding business operations, growth prospects, and financial stability.
- Investor Losses: Due to these alleged misrepresentations, Erasca's common stock traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, highlighting the legal risks and potential financial implications facing the company.
- Law Firm's Strength: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Class Action Lawsuits Against BitGo and Others
- BitGo Lawsuit Reminder: A class action lawsuit against BitGo Holdings, Inc. alleges that the company failed to disclose the severe risks posed by falling digital asset prices to its financial performance, urging investors who purchased shares and suffered losses to apply for lead plaintiff status by August 7, 2026.
- ADMA Legal Issues: ADMA Biologics, Inc. faces a class action lawsuit claiming misleading statements made between August 9, 2024, and March 25, 2026, with investors needing to apply for lead plaintiff status by August 10, 2026, to protect their rights.
- Erasca Class Action: The class action lawsuit against Erasca, Inc. alleges failure to disclose material facts regarding ERAS-0015 between January 14, 2025, and April 26, 2026, with affected investors required to apply for lead plaintiff status by August 10, 2026.
- Legal Firm Overview: Holzer & Holzer, LLC, a top-rated securities litigation law firm, has been dedicated to vigorously representing shareholders since 2000, recovering hundreds of millions of dollars for victims of corporate misconduct.
See More
Erasca Faces Class Action Lawsuit Risks
- Class Action Notice: Robbins Geller Rudman & Dowd LLP announces that shareholders of Erasca, Inc. can apply to be lead plaintiffs in a class action lawsuit by August 10, 2026, concerning stock purchases between January 14, 2025, and April 26, 2026, highlighting investor concerns over potential legal risks facing the company.
- Legal Allegations Details: The lawsuit alleges that Erasca and its executives violated the Securities Exchange Act of 1934 by failing to disclose issues with ERAS-0015's clinical data, which may lead to patent and trade secret infringements, indicating a lack of transparency in the company's R&D processes.
- Stock Price Volatility: Following the disclosure of a patent dispute with Revolution Medicines, Inc. on April 27, 2026, Erasca's stock price fell nearly 11%, and subsequent clinical data release caused a further decline of over 48%, reflecting extreme market concerns regarding the company's future prospects.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can seek lead plaintiff status, indicating that the legal framework provides a pathway for investors to protect their interests while also reflecting the significant legal challenges that may impact the company's future financing capabilities.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 during the class period, resulting in investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and track record in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Erasca Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Notification: Kahn Swick & Foti LLC has notified investors that Erasca, Inc. is facing a class action lawsuit aimed at recovering losses for those who purchased shares between January 14, 2025, and April 26, 2026, indicating potential risks related to improper disclosures by the company.
- Lawsuit Background: The lawsuit alleges that Erasca and certain executives failed to disclose material information during the class period, violating federal securities laws, specifically regarding improper comparisons of preclinical data for the ERAS-0015 product, which may jeopardize patent and trade secret protections.
- Investor Action Guidance: Affected investors must request to be appointed as lead plaintiff by August 10, 2026, although participation in any recovery does not require serving as lead plaintiff, providing a crucial legal avenue for investors to seek compensation for their losses.
- Law Firm Background: Kahn Swick & Foti is one of the nation's premier securities litigation law firms, ranked among the top ten nationally based on total settlement value in the past year, demonstrating its expertise in recovering losses for investors stemming from corporate fraud or misconduct.
See More
Erasca Faces Securities Class Action After 48% Stock Drop
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) due to patent infringement allegations, resulting in a loss of over $2.8 billion in market capitalization, highlighting the company's vulnerability in the competitive precision oncology market.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors regarding the safety and intellectual property protection of ERAS-0015, which could severely impact the company's future financing and market trust.
- Patient Incident: A patient died after experiencing adverse effects one month post-treatment with ERAS-0015, raising significant concerns among the public and investors about the safety profile of Erasca's products.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's product, potentially leading to intellectual property disputes that could damage the company's reputation and market position.
See More
Erasca Faces Securities Fraud Class Action Lawsuit
- Class Action Reminder: Bernstein Liebhard LLP reminds investors of Erasca, Inc. (NASDAQ: ERAS) about the August 10, 2026 deadline for a securities fraud class action lawsuit, urging investors to submit forms promptly to participate in the litigation.
- Lawsuit Background: The lawsuit represents investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, alleging violations of the Securities Exchange Act of 1934 by the company and certain senior officers for making materially false and misleading statements regarding business operations, growth prospects, and financial stability.
- Investor Losses: Due to these alleged misrepresentations, Erasca's common stock traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, highlighting the legal risks and potential financial implications facing the company.
- Law Firm's Strength: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, demonstrating its expertise and influence in protecting investor rights.
See More
Investors Alert: Class Action Lawsuits Against BitGo and Others
- BitGo Lawsuit Reminder: A class action lawsuit against BitGo Holdings, Inc. alleges that the company failed to disclose the severe risks posed by falling digital asset prices to its financial performance, urging investors who purchased shares and suffered losses to apply for lead plaintiff status by August 7, 2026.
- ADMA Legal Issues: ADMA Biologics, Inc. faces a class action lawsuit claiming misleading statements made between August 9, 2024, and March 25, 2026, with investors needing to apply for lead plaintiff status by August 10, 2026, to protect their rights.
- Erasca Class Action: The class action lawsuit against Erasca, Inc. alleges failure to disclose material facts regarding ERAS-0015 between January 14, 2025, and April 26, 2026, with affected investors required to apply for lead plaintiff status by August 10, 2026.
- Legal Firm Overview: Holzer & Holzer, LLC, a top-rated securities litigation law firm, has been dedicated to vigorously representing shareholders since 2000, recovering hundreds of millions of dollars for victims of corporate misconduct.
See More
Erasca Faces Class Action Lawsuit Risks
- Class Action Notice: Robbins Geller Rudman & Dowd LLP announces that shareholders of Erasca, Inc. can apply to be lead plaintiffs in a class action lawsuit by August 10, 2026, concerning stock purchases between January 14, 2025, and April 26, 2026, highlighting investor concerns over potential legal risks facing the company.
- Legal Allegations Details: The lawsuit alleges that Erasca and its executives violated the Securities Exchange Act of 1934 by failing to disclose issues with ERAS-0015's clinical data, which may lead to patent and trade secret infringements, indicating a lack of transparency in the company's R&D processes.
- Stock Price Volatility: Following the disclosure of a patent dispute with Revolution Medicines, Inc. on April 27, 2026, Erasca's stock price fell nearly 11%, and subsequent clinical data release caused a further decline of over 48%, reflecting extreme market concerns regarding the company's future prospects.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can seek lead plaintiff status, indicating that the legal framework provides a pathway for investors to protect their interests while also reflecting the significant legal challenges that may impact the company's future financing capabilities.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 during the class period, resulting in investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and track record in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Erasca Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Notification: Kahn Swick & Foti LLC has notified investors that Erasca, Inc. is facing a class action lawsuit aimed at recovering losses for those who purchased shares between January 14, 2025, and April 26, 2026, indicating potential risks related to improper disclosures by the company.
- Lawsuit Background: The lawsuit alleges that Erasca and certain executives failed to disclose material information during the class period, violating federal securities laws, specifically regarding improper comparisons of preclinical data for the ERAS-0015 product, which may jeopardize patent and trade secret protections.
- Investor Action Guidance: Affected investors must request to be appointed as lead plaintiff by August 10, 2026, although participation in any recovery does not require serving as lead plaintiff, providing a crucial legal avenue for investors to seek compensation for their losses.
- Law Firm Background: Kahn Swick & Foti is one of the nation's premier securities litigation law firms, ranked among the top ten nationally based on total settlement value in the past year, demonstrating its expertise in recovering losses for investors stemming from corporate fraud or misconduct.
See More
Erasca Faces Securities Class Action After 48% Stock Drop
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) due to patent infringement allegations, resulting in a loss of over $2.8 billion in market capitalization, highlighting the company's vulnerability in the competitive precision oncology market.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors regarding the safety and intellectual property protection of ERAS-0015, which could severely impact the company's future financing and market trust.
- Patient Incident: A patient died after experiencing adverse effects one month post-treatment with ERAS-0015, raising significant concerns among the public and investors about the safety profile of Erasca's products.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's product, potentially leading to intellectual property disputes that could damage the company's reputation and market position.
See More
